105 related articles for article (PubMed ID: 17673375)
1. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
Ludwig AH; Bujko M; Bidzinski M; Kupryjańczyk J
Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
[TBL] [Abstract][Full Text] [Related]
2. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
5. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer.
Mariatos G; Bothos J; Zacharatos P; Summers MK; Scolnick DM; Kittas C; Halazonetis TD; Gorgoulis VG
Cancer Res; 2003 Nov; 63(21):7185-9. PubMed ID: 14612512
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A
Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792
[TBL] [Abstract][Full Text] [Related]
7. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.
Mizuno K; Osada H; Konishi H; Tatematsu Y; Yatabe Y; Mitsudomi T; Fujii Y; Takahashi T
Oncogene; 2002 Apr; 21(15):2328-33. PubMed ID: 11948416
[TBL] [Abstract][Full Text] [Related]
8. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of the CHFR gene in digestive tract cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(3A):1791-5. PubMed ID: 16827108
[TBL] [Abstract][Full Text] [Related]
11. Coding region polymorphisms in the CHFR mitotic stress checkpoint gene are associated with colorectal cancer risk.
Kang HC; Kim IJ; Jang SG; Hong SH; Hwang JA; Shin HR; Park JG
Cancer Lett; 2008 Feb; 260(1-2):170-9. PubMed ID: 18079053
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
14. Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer.
Bhawal UK; Tsukinoki K; Sasahira T; Sato F; Mori Y; Muto N; Sugiyama M; Kuniyasu H
Oncol Rep; 2007 Oct; 18(4):817-24. PubMed ID: 17786341
[TBL] [Abstract][Full Text] [Related]
15. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer.
Liu MC; Choong DY; Hooi CS; Williams LH; Campbell IG
Cancer Lett; 2007 Mar; 247(1):91-7. PubMed ID: 16644110
[TBL] [Abstract][Full Text] [Related]
18. A commonly deleted region in ovarian cancer on chromosome 19p13.3, not including the OAZ1 gene.
Yanaihara N; Okamoto A; Matsufuji S
Int J Oncol; 2003 Sep; 23(3):567-75. PubMed ID: 12888889
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma.
Francis-Thickpenny KM; Richardson DM; van Ee CC; Love DR; Winship IM; Baguley BC; Chenevix-Trench G; Shelling AN
Br J Cancer; 2001 Sep; 85(5):687-91. PubMed ID: 11531253
[TBL] [Abstract][Full Text] [Related]
20. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
